A Trial of Single Autologous Transplant With or Without Consolidation Therapy Versus Tandem Autologous Transplant With Lenalidomide Maintenance for Patients With Multiple Myeloma (BMT CTN 0702)

Trial Profile

A Trial of Single Autologous Transplant With or Without Consolidation Therapy Versus Tandem Autologous Transplant With Lenalidomide Maintenance for Patients With Multiple Myeloma (BMT CTN 0702)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms StaMINA Study
  • Most Recent Events

    • 06 Jun 2017 Exploratory results of the association between progression free survival and overall survival and baseline multiple myeloma response, risk category, and treatments presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 May 2017.
    • 07 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top